A Study of BLB-201 RSV Vaccine in Infants and Children (NCT05655182)
A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children
🩺 Plain-English Summary (8th-Grade Level)
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.
Who can join: Review the eligibility criteria below.
Location: Paradigm Clinical Research — La Mesa, California
Age range: 6 Months to 5 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Paradigm Clinical Research — La Mesa, California
- Paradigm Clinical Research - Modesto — Modesto, California
- University of California, San Diego — San Diego, California
- Paradigm Clinical Research Centers, LLC - Colorado, 1550 South Potomac Street, Suite 340 — Aurora, Colorado
- Velocity Clinical Research, Boise — Meridian, Idaho
- Clinical Research Prime — Rexburg, Idaho
- AMR Newton — Newton, Kansas
- Velocity Clinical Research - Lafayette — Lafayette, Louisiana
- Michigan Institute of Research — Allen Park, Michigan
- Velocity Clinical Research, Grand Island — Grand Island, Nebraska
- Be Well Clinical Studies — Lincoln, Nebraska
- Velocity Clinical Research, Cleveland — Beachwood, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Tribe Clinical Research, LLC Parkside Pediatrics — Greenville, South Carolina
- Velocity Clinical Research, Austin — Cedar Park, Texas
- Baylor College of Medicine — Houston, Texas
📞 Contact the Study Coordinator
Phone: (585) 313-0027
Email: HRadziewicz@bluelakebiotechnology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Respiratory Syncytial Virus Infections
- Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá — Bogotá,
- Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above — Mobile, Alabama
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study — Birmingham, Alabama
- A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant — Lexington, Kentucky
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease — Los Angeles, California
Explore by condition: All Respiratory Syncytial Virus Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.